**Cymbalta Recalled: Impurities Pose Cancer Threat**

ZAGO 𝕸𝖊𝖉𝖎𝖆

You need 2 min read

·

Post on Oct 24, 2024

52 visitor like this post

Share

Cymbalta Recalled: Impurities Pose Cancer Threat

A recent recall of the popular antidepressant Cymbalta has sent shockwaves through the medical community and raised serious concerns for patients. The recall, issued by the manufacturer Eli Lilly and Company, is due to the presence of N-Nitroso-venlafaxine, a potentially cancer-causing impurity found in certain batches of the medication.

What is Cymbalta?

Cymbalta (venlafaxine) is a serotonin-norepinephrine reuptake inhibitor (SNRI), a class of medications commonly prescribed for the treatment of depression, anxiety disorders, and chronic pain conditions.

The Impurity: N-Nitroso-venlafaxine

N-Nitroso-venlafaxine is a nitrosamine, a group of chemicals known to be potentially carcinogenic. Exposure to nitrosamines can increase the risk of developing certain types of cancer, including liver, stomach, and bladder cancer.

Recall Details

The recall affects specific batches of Cymbalta capsules manufactured by Eli Lilly and Company. The company has voluntarily initiated the recall out of an abundance of caution and to ensure patient safety.

Patients who have received Cymbalta should check their medication bottles to see if they have a batch number that is included in the recall.

What Should Patients Do?

If you have Cymbalta and believe it may be included in the recall, you should immediately contact your healthcare provider or pharmacist. They can advise you on the appropriate course of action, which may include:

• Stopping the medication immediately and seeking alternative treatment options.
• Returning the medication to your pharmacy.
• Disposing of the medication properly.

Do not attempt to dispose of medication down the drain or in the trash without proper instructions.

The Importance of Patient Safety

This recall highlights the crucial importance of medication safety and the need for robust regulatory oversight. Patients should be aware of any potential risks associated with their medications and report any concerns to their healthcare provider immediately.

Eli Lilly and Company has stated that they are committed to ensuring the safety of their products and are working closely with regulatory agencies to investigate the root cause of the impurity.

This situation underscores the ongoing challenges in drug manufacturing and the critical importance of vigilant monitoring for potentially harmful impurities. Patients should stay informed about any recalls or safety alerts and consult with their healthcare providers for personalized advice.

This article is for informational purposes only and should not be considered medical advice. Always consult with a healthcare professional for any questions or concerns regarding your health or medication.